Endpoints News 生物医药· Kyle LaHucik·· 29 天前AI 评分48
Gilead支付12.8亿美元首付款引进PepStar口服IL-23药物
Gilead strikes $1.3B upfront China deal for oral IL-23 drug
AI 导读
Gilead将向PepStar Therapeutics支付12.8亿美元首付款,引进其处于临床开发阶段的口服IL-23药物,交易涉及炎症治疗市场。原文正文被订阅墙截断,未给出试验期别与适应症。
正文
Gilead is going to Shanghai for its latest expansion in the hot inflammation market, dishing out $1.28 billion upfront to PepStar Therapeutics for a Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news